Press release

ADA’s William T. Cefalu, MD, to Testify on the Rising Cost of Insulin Before the Oversight and Investigations Subcommittee of the U.S. House of Representatives’ Committee on Energy & Commerce on Tuesday, April 2

March 29, 2019 | Arlington, Virginia
ada-a_comms_logo

American Diabetes Association’s (ADA’s) Chief Scientific, Medical and Mission Officer, William T. Cefalu, MD, will testify before the U.S. House of Representatives Committee on Energy & Commerce’s Oversight and Investigations Subcommittee during their Prices” hearing on Tuesday, April 2, 2019 at 10:30 a.m. Dr. Cefalu will address the rising costs of insulin, which impact millions of Americans with diabetes who rely on this life-sustaining medication. Dr. Cefalu will share the ADA’s extensive efforts during the past five years to understand and address the issue of rising insulin costs, the impact of high insulin costs on people with diabetes and their families, and the work of the ADA’s leadership and the ADA’s Insulin Access and Affordability Working Group to gain transparency and knowledge about the insulin supply chain. The ADA is steadfastly committed to continuing to work toward long-term solutions that ensure affordable access to insulin for all who need it. 

What: U.S. House of Representatives Committee on Energy & Commerce, Oversight and Investigations Subcommittee Hearing “Priced Out of a Lifesaving Drug: The Human Impact of Rising Insulin Prices”

Who: William T. Cefalu, MD, Chief Scientific, Medical and Mission Officer, American Diabetes Association

U.S. House of Representatives Committee on Energy & Commerce, Oversight and Investigations Subcommittee:

  • Representative Diana DeGette, (D-CO), Chair, Oversight and Investigations Subcommittee

  • Representative Brett Guthrie, (R-KY), Ranking Member, Oversight and Investigations Subcommittee

Where: 2322 Rayburn House Office Building

When: Tuesday, April 2, 2019, 10:30 a.m. ET

Additional panelists invited by the Subcommittee:

  • Gail DeVore, Patient Advocate, Coloradan living with type1 diabetes for 47 years

  • Alvin C. Powers, MD, on behalf of Endocrine Society; Division Director, Division of Diabetes, Endocrinology & Metabolism, Joe C. Davis Chair in Biomedical Science, Professor of Molecular Physiology & Biophysics, Vanderbilt University; a member of the ADA’s Insulin Affordability and Access Working Group; and the ADA’s 2017 President of Medicine and Science 

  • Kasia J. Lipska, MD, Yale-New Haven Medical Center for Outcomes Research and Evaluation, Yale University 

  • Christel Marchand Aprigliano, MS, CEO, Diabetes Patient Advocacy Coalition

  • Aaron J. Kowalski, PhD, Chief Mission Officer, JDRF

# # #

, About the American Diabetes Association

Every day more than 4,000 people are newly diagnosed with diabetes in America. Nearly 115 million Americans have diabetes or prediabetes and are striving to manage their lives while living with the disease. The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For nearly 80 years the ADA has been driving discovery and research to treat, manage and prevent diabetes, while working relentlessly for a cure. We help people with diabetes thrive by fighting for their rights and developing programs, advocacy and education designed to improve their quality of life. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).